by Elec23 | Jul 30, 2026 | News&events, VisMederi
A new scientific publication from VisMederi has recently been published in Influenza and Other Respiratory Viruses. The study, “Impact of ABO Blood System on Immunogenicity and Vaccine Efficacy of COVID-19 Booster Vaccination,” analyzed data from 3,066...
by Elec23 | Jul 27, 2026 | News&events, VisMederi
VisMederi announces the successful qualification of a standardized, high-throughput Luminescence Serum Bactericidal Assay (L-SBA) — a key milestone in supporting the evaluation of next-generation Shigella vaccines. This achievement reflects the strength of an...
by Elec23 | Jul 1, 2026 | News&events, VisMederi
First identified in Uganda in 2007, Bundibugyo ebolavirus is one of the species of the Ebola virus. Although it has historically shown a lower case fatality rate than some other Ebola virus species, typically between 25% and 40%, it remains a serious public health...
by Elec23 | Jun 19, 2026 | News&events, VisMederi
From kit design and manufacturing to biological sample management and laboratory testing, VisMederi offers a fully integrated solution for clinical trials and research programs worldwide. VisMederi, a company specialized in vaccine evaluation through advanced...
by Elec23 | Jun 18, 2026 | News&events, VisMederi
VisMederi and CEVAC, a Belgian vaccine research center comprising a Clinical Trial Unit and an Immunomonitoring Laboratory, have signed a Memorandum of Understanding (MoU) to strengthen their collaboration in vaccine clinical trials, a core area of expertise for both...
